ESMO 2025 preview – Astellas's third Claudin18.2 shot
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
The company sticks with EZH2, despite others adding EZH1 inhibition.
